|
Status |
Public on Feb 20, 2021 |
Title |
Targeting PDGFRa-activated Glioblastoma through Specific Inhibition of SHP-2-mediated Signaling |
Organism |
Mus musculus |
Experiment type |
Expression profiling by high throughput sequencing
|
Summary |
SHP-2 is a nonreceptor protein tyrosine phosphatase encoded by the PTPN11 gene and is critical for PDGFR-driven gliomagenesis. SHP099, a novel and potent SHP-2 inhibitor, preferentially attenuated the tumorigenicity of GBM and glioma stem-like cells (GSCs) compared to normal brain cells or neural progenitor cells in vitro. Delivered orally, SHP099 crosses the blood-brain barrier (BBB) and accumulates at efficacious concentrations in the brains, as determined using two different orthotopic xenograft models. SHP099 inhibited tumor growth and extended survival in activated PDGFR-signaling xenografts alone and in combination with first-line chemotherapeutic agent, temozolomide (TMZ). This study highlights SHP-2 inhibitor SHP099 potential for treatment of clinical GBM in combination with TMZ.
|
|
|
Overall design |
Examination of effects of SHP-2 inhibitor SHP099 treatment on differential gene expression in glioma cells.
|
|
|
Contributor(s) |
Feng H |
Citation(s) |
31232447 |
|
Submission date |
Feb 21, 2019 |
Last update date |
May 23, 2021 |
Contact name |
Haizhong Feng |
E-mail(s) |
fenghaizhong@sjtu.edu.cn
|
Phone |
862168383921
|
Organization name |
Shanghai Jiao Tong University
|
Department |
Ren Ji Hospital
|
Street address |
Pujian Road 160
|
City |
Shanghai |
State/province |
Shanghai |
ZIP/Postal code |
200127 |
Country |
China |
|
|
Platforms (1) |
|
Samples (6)
|
GSM3617816 |
Ink4a/Arf-/-/PDGFRa/PDGF-A [R17023449LR01_S9_L006] |
GSM3617817 |
Ink4a/Arf-/-/PDGFRa/PDGF-A [R17023449LR01_S9_L007] |
GSM3617818 |
Ink4a/Arf-/-/PDGFRa/PDGF-A [R17023449LR01_S10_L006] |
GSM3617819 |
Ink4a/Arf-/-/PDGFRa/PDGF-A [R17023449LR01_S10_L007] |
GSM3617820 |
Ink4a/Arf-/-/PDGFRa/PDGF-A [R17023449LR01_S11_L006] |
GSM3617821 |
Ink4a/Arf-/-/PDGFRa/PDGF-A [R17023449LR01_S11_L007] |
|
Relations |
BioProject |
PRJNA523607 |
SRA |
SRP186500 |